Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania. Show more

Location: 3805 Old Easton Road, Doylestown, PA, 18902, United States | Website: https://aprea.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

6.50M

52 Wk Range

$0.96 - $5.00

Previous Close

$1.03

Open

$1.00

Volume

88,338

Day Range

$0.99 - $1.14

Enterprise Value

-7.281M

Cash

13.72M

Avg Qtr Burn

-3.361M

Insider Ownership

21.24%

Institutional Own.

25.68%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ATRN-119 Details Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APR-1051 Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eprenetapopt (APR-246) + azacitidine Details Acute myeloid leukemia, Cancer, Myelodysplastic syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
APR-548 + azacitidine Details Mutant Myelodysplastic Syndromes	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eprenetapopt (APR-246) + Azacitidine Details Blood disorder, Myelodysplastic syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.